Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by First Bank & Trust

First Bank & Trust cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 26.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,386 shares of the medical research company's stock after selling 852 shares during the quarter. First Bank & Trust's holdings in Thermo Fisher Scientific were worth $1,241,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in TMO. Legacy Investment Solutions LLC acquired a new stake in shares of Thermo Fisher Scientific in the third quarter valued at about $26,000. Peterson Financial Group Inc. purchased a new stake in Thermo Fisher Scientific during the 3rd quarter worth approximately $27,000. Barrett & Company Inc. acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $28,000. Missouri Trust & Investment Co acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $29,000. Finally, Endeavor Private Wealth Inc. acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at $30,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the completion of the sale, the chief executive officer now directly owns 111,192 shares in the company, valued at approximately $58,960,669.92. This trade represents a 8.25 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the transaction, the executive vice president now directly owns 16,363 shares of the company's stock, valued at approximately $9,582,009.17. This represents a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 20,125 shares of company stock valued at $11,231,699 over the last quarter. Company insiders own 0.34% of the company's stock.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of research reports. Stifel Nicolaus dropped their target price on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a "buy" rating for the company in a report on Thursday, October 24th. Wells Fargo & Company raised their price objective on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an "overweight" rating in a research report on Friday, January 31st. StockNews.com raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, January 14th. Scotiabank raised their target price on Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a "sector perform" rating in a research note on Monday, February 3rd. Finally, Robert W. Baird decreased their price target on Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating on the stock in a research note on Thursday, October 24th. Four analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and an average target price of $658.00.

Thermo Fisher Scientific Stock Down 1.0 %

TMO stock traded down $5.28 during mid-day trading on Friday, reaching $532.55. The company had a trading volume of 1,613,862 shares, compared to its average volume of 2,087,588. Thermo Fisher Scientific Inc. has a fifty-two week low of $493.30 and a fifty-two week high of $627.88. The company has a market capitalization of $203.70 billion, a price-to-earnings ratio of 32.22, a price-to-earnings-growth ratio of 2.95 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The firm has a fifty day simple moving average of $548.36 and a 200 day simple moving average of $568.15.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has authorized a share repurchase program on Friday, November 15th that allows the company to buyback $4.00 billion in outstanding shares. This buyback authorization allows the medical research company to buy up to 2% of its shares through open market purchases. Shares buyback programs are often an indication that the company's leadership believes its stock is undervalued.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be paid a $0.43 dividend. The ex-dividend date is Friday, March 14th. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.32%. Thermo Fisher Scientific's payout ratio is 9.44%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.